Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27527719 | 0.94 | ADORA1 (0.50) | ADORA1ADORA2AADORA2BMAPK14MAPK13 | |
| SCHEMBL5450214 | 0.87 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BADORA3MAPK14 | |
| SCHEMBL7211859 | 0.85 | MAPK14 (0.59) | ADORA1ADORA2AADORA3MAPK14MAPK13 | |
| SCHEMBL7211818 | 0.85 | MAPK14 (0.52) | ADORA1ADORA2AADORA2BADORA3MAPK14 | |
| SCHEMBL7234155 | 0.85 | MAPK14 (0.52) | ADORA1ADORA2AADORA2BADORA3MAPK14 | |
| SCHEMBL7210170 | 0.83 | MAPK14 (0.58) | ADORA1ADORA2AMAPK14MAPK13MAPK12 | |
| SCHEMBL7216477 | 0.82 | ADORA1 (0.47) | ADORA1ADORA2AADORA2BMAPK14MAPK13 | |
| SCHEMBL7215273 | 0.80 | PTGS2 (0.53) | ADORA1ADORA2AMAPK14MAPK13MAPK12 | |
| SCHEMBL7215140 | 0.79 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BMAPK14MAPK13 | |
| SCHEMBL7215201 | 0.79 | CYP1A2 (0.55) | ADORA1ADORA2AADORA2BMAPK14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |